News Search Results
May 01, 2025, 18:00 ET Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
May 01, 2025, 17:31 ET EPIDIOLEX Continues to Lead the Way in Cannabinoid-Based Epilepsy Treatment | DelveInsight
Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, among others.
More news about: DelveInsight Business Research, LLP
May 01, 2025, 16:05 ET BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
Conference ID: 4327591 About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
May 01, 2025, 16:01 ET AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
May 01, 2025, 12:19 ET Rosalind Franklin University Incubator Company Announces Positive Anti-Fibrotic Effects in Lung Fibrosis Model
NORTH CHICAGO, Ill., May 1, 2025 /PRNewswire/ -- BLR Bio, a biotechnology company in Rosalind Franklin University's
More news about: Rosalind Franklin University of Medicine and Science
May 01, 2025, 09:14 ET David Anderson Named a Top Healthcare Investor of 2025 by GrowthCap
leadership, and ability to navigate the ever-evolving healthcare landscape. Their areas of focus include healthcare software, medical technologies, biotechnology, healthcare services, the connected patient experience, and other related areas. In addition to their investment acumen, these investors have demonstrated
More news about: Ampersand Capital Partners
May 01, 2025, 09:00 ET S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate
More news about: S&E bio Co., Ltd.
May 01, 2025, 09:00 ET Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer
Medical Officer. Dr. Knobil, who previously served as the Chief Medical Officer of GSK, brings more than 25 years of experience in pharmaceutical and biotechnology research and development resulting in regulatory approval and launch of blockbuster medicines.
More news about: Altesa Biosciences Inc.
May 01, 2025, 09:00 ET Former USAA CEO Wayne Peacock, and Foot Locker Nonexecutive Chair Dona Young, NACD.DC, to Cochair NACD 2025 Blue Ribbon Commission on Board-CEO Relationship
Maggie Wilderotter — CEO, Grand Reserve Inn; Chairman and CEO, Wilderotter Vineyards; Chair, DocuSign; Director, Costco Wholesale Corporation, Sana Biotechnology, Tanium and Sonoma BiotherapeuticsAbout NACD The National Association of Corporate Directors® (NACD®)
More news about: National Association of Corporate Directors
May 01, 2025, 08:33 ET Mivium Completes $5 Million Funding Round
traditional silicon-based semiconductors in industries such as power electronics, aerospace, telecommunications, AI infrastructure, photonics, and biotechnology. Mivium's team comprises experts in material science and semiconductor manufacturing, driving the company's innovative approach. Media
More news about: Mivium, Inc.
May 01, 2025, 08:18 ET Everads Announces Five Abstracts Accepted for Presentation at ARVO 2025, Including First-in-Human Results Using its Novel Suprachoroidal Injector
Israel, May 1, 2025 /PRNewswire/ -- Everads Therapy, a clinical-stage biotechnology company advancing suprachoroidal delivery of therapeutics for targeted, office-based treatment of diseases affecting the back of the eye, today
More news about: Everads Therapy
May 01, 2025, 08:00 ET Sapience Therapeutics Announces Oral Presentation at the Upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Featuring Lucicebtide Phase 2 Results
N.Y., May 1, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
May 01, 2025, 08:00 ET AmacaThera and Merck Animal Health Announce Collaboration in Animal Health
TORONTO, May 1, 2025 /PRNewswire/ - AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding evaluation and option agreement with Merck Animal Health to develop long-acting
More news about: AmacaThera Inc.
May 01, 2025, 07:00 ET Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
May 01, 2025, 07:00 ET Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
treatments and better management strategies to improve patient outcomes and reduce mortality rates. About Pincell srl PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly
More news about: Scinai Immunotherapeutics Ltd.
May 01, 2025, 06:45 ET Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 01, 2025, 05:45 ET Contact The Gross Law Firm by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
May 1, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
May 01, 2025, 04:00 ET S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate
More news about: S&E bio Co., Ltd.
May 01, 2025, 03:00 ET Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer
financing round in 2024. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start–up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics Ltd
Apr 30, 2025, 17:51 ET RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing
Fisher. "We're excited to work with the team to expand our Contract Development Manufacturing Organization (CDMO) services and support our biotechnology partners through the research and optimization, process development and manufacturing of critical treatments." Consistent with global best
More news about: RoosterBio, Inc.
Apr 30, 2025, 16:05 ET REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Apr 30, 2025, 16:00 ET Rgenta Therapeutics Announces Presentation of Preclinical Data from Proprietary RSwitch Technology at the American Society of Gene And Cell Therapy (ASGCT) 2025 Annual Meeting
Mass., April 30, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
Apr 30, 2025, 15:17 ET Fluorescence Microscopy Market to Reach $1.3 Billion by 2029
targeted therapies. Understanding Cellular Processes: Real-time observation of cellular mechanisms helps in medical research and biotechnology advances. Research Funding: Increased funding supports new technologies, equipment, and researcher training. Miniaturization:
More news about: BCC Research LLC
Apr 30, 2025, 10:30 ET Surface Disinfectant Market worth US$4.38 billion by 2030 with 7.6% CAGR | MarketsandMarkets™
on end user, the surface disinfectant market is segmented into hospitals, clinics, and ASCs, diagnostic laboratories, pharmaceutical & biotechnology companies, and research laboratories. The hospitals, clinics, and ASCs segment is expected to grow at the fastest CAGR during the forecast period.
More news about: MarketsandMarkets
Apr 30, 2025, 09:05 ET Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer
DIEGO, April 30, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing personalized, autologous cell therapies, has appointed Dalen Meeter, CPA, MBA, as Chief Financial
More news about: Aspen Neuroscience, Inc.